Respirology
RESP · guidelines, resources & primary literature
Guidelines & Resources
General
- Inhalation Devices — RxFiles
- Hands vs Lungs Approach — RxFiles
- Inhaler Techniques — RxFiles
- Environmental Impact Inhaler Guide — BCInhalers
- ERS/ATS Criteria for Routine Lung Function Tests — ERS/ATS 2022
- HRCT Basic Interpretation — RadiologyAssistant
- HRCT Common Diagnoses — RadiologyAssistant
- HRCT ILD Patterns — RadiologyAssistant
- Hypersensitivity Pneumonitis Exposure Checklist — ERS 2020
- Personal Acid-Base Notes
- Lung POCUS — UBC IM POCUS
Asthma
- Asthma Guidelines — CTS 2021
- GINA Summary Guide — GINA 2026
COPD
- Full GOLD Report — GOLD 2026
- GOLD Pocket Guide — GOLD 2026
- COPD — RxFiles
Primary Literature
General
- Does This Patient Have a Pleural Effusion? — JAMA 2014
Asthma
Biologics
- EXTRA — Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy — Ann Intern Med 2011
- SIROCCO — Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists — Lancet 2016
- CALIMA — Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma — Lancet 2016
- ZONDA — Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma — NEJM 2017
- PATHWAY — Tezepelumab in Adults with Uncontrolled Asthma — NEJM 2017
- LIBERTY ASTHMA QUEST — Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma — NEJM 2018
- LIBERTY ASTHMA VENTURE — Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma — NEJM 2018
- NAVIGATOR — Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma — NEJM 2021
- SOURCE — Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma — Lancet Respir Med 2022
- WAYFINDER — Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab — Lancet Respir Med 2026
COPD
Inhaler Therapy
- UPLIFT — Tiotropium in Chronic Obstructive Pulmonary Disease — NEJM 2008
- IMPACT — Single Inhaler Triple versus Dual Bronchodilator Therapy in Chronic Obstructive Pulmonary Disease — NEJM 2018
- TRINITY — Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease — Lancet 2017
- TRILOGY — Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease — Lancet 2016
- ETHOS — Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD — NEJM 2020
- ENHANCE — Lung Function and Safety Outcomes in Patients With Moderate-to-Severe COPD Treated With Ensifentrine — CHEST Pulm 2025 (pooled ENHANCE-1/2 analysis)
Exacerbations
- REDUCE — Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease — JAMA 2013
- ALBERT — Azithromycin for Prevention of Exacerbations of COPD — NEJM 2011
Biologics
ILD
Antifibrotics
- CAPACITY — Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (CAPACITY) — Two Randomised Trials — Lancet 2011
- ASCEND — A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis — NEJM 2014
- INPULSIS-1/2 — Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis — NEJM 2014
- FIBRONEER-IPF — Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis — NEJM 2025
Immunosuppression
- PANTHER-IPF — Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis — NEJM 2012